^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Alymsys (bevacizumab-maly)

    i
    Other names: BEVZ92, MB02
    Company:
    Amneal, Insud Pharma, Nichi-Iko, Pharmaceutical Libbs, Stada
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    2ms
    A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®. (clinicaltrials.gov)
    P1, N=114, Completed, mAbxience Research S.L. | Active, not recruiting --> Completed
    Trial completion
    |
    Alymsys (bevacizumab-maly)
    over1year
    In Silico and In Vitro Evaluation of Bevacizumab Biosimilar MB02 as an Antitumor Agent in Canine Mammary Carcinoma. (PubMed, Animals (Basel))
    Additionally, canine VEGF-induced microvascular endothelial cell proliferation was inhibited in a concentration-dependent manner by MB02 biosimilar. These encouraging results show a high potential for MB02 as a promising therapeutic agent for the management of CMC.
    Preclinical • Journal
    |
    Alymsys (bevacizumab-maly)